Healthcare
Nektar Therapeutics(NKTR)
Live Price
Offline$60.98
+0.10% today
1Y Change
+118.46%
Window
Jun 26, 2025 โ Jun 24, 2026
- Market Cap
- $1.75B
- Revenue Growth
- -43.9%
- EPS Growth
- -12.1%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 26, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nektar Therapeutics (NKTR) is a Healthcare stock with a market cap of $1.75B and listed on NASDAQ. The stock last traded around $60.98 and up 118.5% across the available one-year price window (Jun 26, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of -43.9%, EPS growth of -12.1%, a dividend yield of 0.0%. What stands out right now is revenue -43.9%, EPS -12.1%, free cash flow -17.8% with operating margin -237.9% and ROIC -53.1%. Valuation already assumes a fairly strong business story at price/sales 31.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines NKTR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-43.9% vs +7.6% peer median
Operating Margin
Below sector median
-237.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -43.9% and EPS is at -12.1%, with operating margin around -237.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.2% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -5.0% | -7.7% | -20.1% |
2026 Mar 12, 2026 | +35.5% | +4.1% | +6.4% | +10.1% |
2025 Nov 6, 2025 | +35.1% | +1.5% | -2.1% | +3.2% |
Benchmark Edge
NKTR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NKTR
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NKTR Max Drawdown
-46.54%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NKTR and SPY.
Company Overview
Nektar Therapeutics
NASDAQ Global Select
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
- Leadership
- Howard W. Robin
- IPO Date
- May 3, 1994
- Employees
- 61
- Street Address
- 455 Mission Bay Boulevard South
- Mailing
- San Francisco, CA, 94158
- Region
- San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 415 482 5300
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 31.8
- Price/Book
- 19.5
Growth
- Revenue
- -43.9%
- EPS
- -12.1%
- Free Cash Flow
- -17.8%
Profitability
- Gross Margin
- 99.6%
- Operating Margin
- -237.9%
- Net Margin
- -297.1%
- ROE
- -399.1%
- ROIC
- -53.1%
Balance Sheet
- Debt/Equity
- 1.66
- Current Ratio
- 4.97
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.